Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The EMPOWER Study: Endometriosis Diagnosis Using MicroRNA
NCT04598698 · View on ClinicalTrials.gov ↗
Study Summary
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visits for collection of blood and saliva and completion of study questionnaires.
Conditions Studied
Study Locations (20)
Illinois
- Northwestern Medicine — Chicago
- NorthShore University HealthSystem — Evanston
- The Advanced Gynecologic Surgery Institute — Park Ridge
California
- Stanford University Hospital — Palo Alto
- Center for Special Minimally Invasive & Robotic Surgery — Woodside
Delaware
- Christiana Care — Newark
- RAD Fertility — Newark
Ohio
- University Hospitals — Cleveland
- Cleveland Clinic — Cleveland
Pennsylvania
- Penn State Health — Hershey
- Hospital of the University of Pennsylvania — Philadelphia
Connecticut
- Yale University — New Haven
District of Columbia
- MedStar Washington Hospital Center — Washington D.C.
Florida
- University of South Florida — Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2024-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04598698
The ClinicalTrials.gov registry entry for NCT04598698 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dot Laboratories, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04598698 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Illinois, California, Delaware. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04598698 about?
NCT04598698 is a clinical study titled "The EMPOWER Study: Endometriosis Diagnosis Using MicroRNA". Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal ris...
What is the current status of trial NCT04598698?
This trial is currently active not recruiting. The enrollment target is 750 participants. The study started on 2020-11-02. Estimated completion is 2024-12.
What conditions does trial NCT04598698 study?
This clinical trial studies the following conditions: Endometriosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT04598698?
This trial is sponsored by Dot Laboratories, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04598698 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.